Procurement Summary
Country : USA
Summary : Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Deadline : 18 Oct 2023
Other Information
Notice Type : Tender
TOT Ref.No.: 89662616
Document Ref. No. : HT9402-23-Q-9404
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Description
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: November 2023: The following drug classes/subclass will be reviewed
a. Akeega - Janssen - Oncological Agents - Subclass: NA
b. Lodoco - Tarsus - Cardiovascular Agents Miscellaneous - Subclass: NA
c. Sohonos - Ipsen - Skeletal Muscle Relaxants and Combinations - Subclass: NA
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-23-Q-9404.
Pre-proposal teleconference is on September 28, 2023, details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated i...
Active Contract Opportunity Notice ID HT9402-23-Q-9404 Related Notice Department/Ind. Agency DEPT OF DEFENSE Sub-tier DEFENSE HEALTH AGENCY (DHA) Office DEFENSE HEALTH AGENCY
General Information
Contract Opportunity Type: Solicitation (Original)
All Dates/Times are: (UTC-05:00) CENTRAL STANDARD TIME, CHICAGO, USA
Original Published Date: Sep 27, 2023 11:51 am CDT
Original Date Offers Due: Oct 18, 2023 12:00 pm CDT
Inactive Policy: Manual
Original Inactive Date: Apr 18, 2024
Initiative: None
Classification
Original Set Aside:
Product Service Code: 6505 - DRUGS AND BIOLOGICALS
NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing
Place of Performance: San Antonio, Tx 78230 USA
Documents
Tender Notice
RFQ-HT9402-23-Q-9404-NAD.pdf
Price-Appendix--Akeega--Oncological-Agents--NA.xlsx
Price-Appendix--Lodoco--Cardiovascular-Agents-Misc--NA.xlsx
Price-Appendix--Sohonos--Skeletal-Muscle-Relaxants--NA.xlsx
Price-Appendix-FAQ-NAD.pdf
DoD-Formulary-Placement-of-FDA-Newly-Approved-Drugs.pdf